Conivaptan
CAS: 210101-16-9
Ref. 3D-FC159956
10mg | 95,00 € | ||
25mg | 151,00 € | ||
50mg | 218,00 € | ||
100mg | 328,00 € | ||
250mg | 410,00 € |
Produktinformation
- Conviaptan
- N-[4-[(4,5-Dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-[1,1′-Biphenyl]-2-carboxamide
- Zinc 12503187
- [1,1'-biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(3H)-yl)carbonyl]phenyl]-
- [1,1′-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-
Conivaptan is a drug that has been shown to be effective in the prevention and treatment of hyponatremia. It was originally developed as an antagonist for vasopressin, a hormone that increases the amount of water excreted by the kidneys. Conivaptan prevents vasopressin from binding to its receptors and therefore reduces the effects of vasopressin on the kidney. The drug can also be used to treat congestive heart failure, cardiac arrhythmia, or chronic heart failure. The optimum concentration of conivaptan is not yet known but it has been shown to bind to receptors in experimental models with high affinity. Concentration-time curves indicate that conivaptan should be administered orally at a dose of 0.4 mg/kg every 12 hours for optimal efficacy.
Chemische Eigenschaften
Technische Anfrage zu: 3D-FC159956 Conivaptan
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.